PremiumThe FlyCartesian Therapeutics reports Q1 EPS (68c) vs ($10.50) last year RNAC Earnings Report this Week: Is It a Buy, Ahead of Earnings? Cartesian Therapeutics announces employment inducement grants PremiumRatingsPromising Growth Potential for Cartesian Therapeutics: Buy Rating Affirmed by Analyst Gil Blum Promising Potential of Cartesian Therapeutics’ Descartes-08 in gMG Treatment: A Buy Recommendation Promising Clinical Data and Future Prospects Drive Buy Rating for Cartesian Therapeutics PremiumThe FlyCartesian price target lowered to $40 from $45 at H.C. Wainwright Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger Cartesian Therapeutics Advances mRNA Therapy Pipeline 
